N.E.W. Advisory Services’s Heron Therapeutics HRTX Stock Holding History

N.E.W. Advisory Services’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$691	Hold	1,619	–	–	﹤0.01%	956
2026 Q1	$1.29K	Hold	1,619	–	–	﹤0.01%	857
2025 Q4	$2.1K	Hold	1,619	–	–	﹤0.01%	790
2025 Q3	$2.04K	Hold	1,619	–	–	﹤0.01%	741
2025 Q2	$3.35K	Hold	1,619	–	–	﹤0.01%	694
2025 Q1	$3.56K	Buy	+1,619	New	+$3.14K	﹤0.01%	739

Other funds holding HRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

N.E.W. Advisory Services's HRTX Position: Q2 2026 in Review

N.E.W. Advisory Services held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 1,619 shares worth $691. The position accounts for ﹤0.01% of the portfolio, ranked #956.

N.E.W. Advisory Services first reported a position in HRTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.56K in Q1 2025. 81 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

N.E.W. Advisory Services held 1,619 shares of Heron Therapeutics worth $691 as of Q2 2026.
N.E.W. Advisory Services left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up ﹤0.01% of N.E.W. Advisory Services's portfolio in Q2 2026, its #956 holding.
N.E.W. Advisory Services first reported a position in Heron Therapeutics in Q1 2025 and has held it in 6 quarters since.
N.E.W. Advisory Services's Heron Therapeutics position peaked at $3.56K in Q1 2025.
81 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on N.E.W. Advisory Services's 13F filing for Q2 2026, filed 6 Aug 2026.